Owing to their limited durability, intravitreal corticosteroids or anti-VEGF agents require frequent intravitreal injections, thereby increasing the risk of cataracts, retinal detachment, endophthalmitis, and hemorrhages (Solomon et al. 2019). This evidence concerns the gene VEGFA and endophthalmitis.